Is HPA-axis dysregulation a driver of IBS symptoms?

The clinical and mechanistic evidence supporting the role of hypothalamic-pituitary-adrenal (HPA) axis dysregulation in irritable bowel syndrome (IBS) is highly established.

Clinical and effectiveness evidence

In clinical cohorts, IBS is consistently characterized by systemic dysregulation of the HPA axis. Studies demonstrate that individuals with IBS exhibit altered cortisol awakening responses, abnormal circadian ACTH and cortisol secretory profiles, and hyper-responsiveness to psychosocial stress challenges compared to healthy controls. These alterations underline a state of hyper-reactivity within the neuroendocrine system that correlates with the severity of gastrointestinal symptoms.

Mechanistic explanations

HPA-axis dysregulation directly drives the core pathophysiological features of IBS—namely, altered gut motility and visceral hypersensitivity—via the gut-brain axis:

• Gastrointestinal motility: Central and peripheral release of corticotropin-releasing hormone (CRH) during HPA-axis activation alters sympathovagal balance. This autonomic shift disrupts coordinated gastrointestinal motor patterns, accelerating colonic transit in diarrhea-predominant IBS (IBS-D) or delaying transit in constipation-predominant IBS (IBS-C).
• Visceral sensitivity: Elevated CRH and cortisol signaling sensitize peripheral nociceptors and alter central pain processing. This lowers the threshold for visceral pain, leading to the clinical presentation of hyperalgesia and allodynia (abdominal pain in response to normal gut distension). Animal models demonstrate that blocking peripheral CRH receptors or normalizing HPA-axis hyperactivity successfully reverses visceral hypersensitivity.

Clinical implications

Understanding the HPA axis as a central mediator in IBS supports the clinical utility of therapies targeting the gut-brain axis. Mind-body interventions (such as cognitive behavioral therapy and gut-directed hypnotherapy) and neuromodulators can help normalize HPA-axis reactivity, offering therapeutic benefit by directly modulating autonomic gut function and pain perception.

Bottom line

HPA-axis dysregulation is a major, scientifically validated driver of IBS pathology. By altering autonomic balance and activating CRH receptors, this neuroendocrine dysfunction directly causes the aberrant gut motility and visceral hypersensitivity that define the disorder.